TR200100841T2 - Antibiyotiklerin kullanımı - Google Patents

Antibiyotiklerin kullanımı

Info

Publication number
TR200100841T2
TR200100841T2 TR2001/00841T TR200100841T TR200100841T2 TR 200100841 T2 TR200100841 T2 TR 200100841T2 TR 2001/00841 T TR2001/00841 T TR 2001/00841T TR 200100841 T TR200100841 T TR 200100841T TR 200100841 T2 TR200100841 T2 TR 200100841T2
Authority
TR
Turkey
Prior art keywords
daptomycin
muscle toxicity
dose
skeletal muscle
toxicity
Prior art date
Application number
TR2001/00841T
Other languages
English (en)
Inventor
Jr Frederick B. Oleson
P. Tally Francis
Original Assignee
Cubist Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200100841(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharmaceuticals, Inc. filed Critical Cubist Pharmaceuticals, Inc.
Publication of TR200100841T2 publication Critical patent/TR200100841T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Bulus, iskelete ait kas toksisitesini asgariye indirmekte iken, daptomisinin tedavi edici olarak etkin bir miktarinin ekullanimini temin etmektedir. Kullanim, 24 saatlik ya da daha fazla olan bir doz miktari zaman araliginda daptomisin ilaç olarak verilmesini temin etmektedir.Bu uzun doz miktari iskelete ait kas toksisitesini asgariye indirmekte ve, bunun daptomisin 'in tesiri ile ilgili oldugu, daptomisinin daha yüksek seviyedeki zivre noktasi kesafetlerine izin vermektedir. Bulus, ayni zamanda, daptomisinden baska lipopeptid antibiyotiklerinin kullanimini temin etmekte olup, bir yandan kas toksisitesi ile sonuçlanmakta olmayan bir dozaj zaman araliginda lipopetid antibiyotiginin tedavi edici olarak etkin bir miktarinin ilaç olarak verilmesi ile istelete ait kas toksisitesini asgariye indirmektedir.
TR2001/00841T 1998-09-25 1999-09-24 Antibiyotiklerin kullanımı TR200100841T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10182898P 1998-09-25 1998-09-25
US12575099P 1999-03-24 1999-03-24

Publications (1)

Publication Number Publication Date
TR200100841T2 true TR200100841T2 (tr) 2002-01-21

Family

ID=26798675

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00841T TR200100841T2 (tr) 1998-09-25 1999-09-24 Antibiyotiklerin kullanımı

Country Status (26)

Country Link
US (2) US6468967B1 (tr)
EP (2) EP1674107B8 (tr)
JP (4) JP4184607B2 (tr)
KR (2) KR20010075327A (tr)
CN (2) CN1530136A (tr)
AT (1) ATE322280T1 (tr)
AU (1) AU764348B2 (tr)
BR (1) BR9914051A (tr)
CA (1) CA2344318C (tr)
CY (3) CY1105556T1 (tr)
DE (3) DE122006000049I1 (tr)
DK (2) DK1115417T3 (tr)
ES (2) ES2259845T3 (tr)
HK (1) HK1040363B (tr)
HU (1) HU230656B1 (tr)
IS (2) IS5890A (tr)
LU (1) LU91254I2 (tr)
NL (1) NL300232I2 (tr)
NO (1) NO20011454L (tr)
NZ (1) NZ510690A (tr)
PL (2) PL203689B1 (tr)
PT (2) PT1674107T (tr)
RU (1) RU2363489C9 (tr)
SI (2) SI1115417T1 (tr)
TR (1) TR200100841T2 (tr)
WO (1) WO2000018419A2 (tr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230656B1 (hu) 1998-09-25 2017-06-28 Cubist Pharmaceuticals Llc Daptomicin alkalmazása
BR0017026A (pt) 1999-12-15 2003-01-07 Cubist Pharm Inc Lipeptìdeos como agentes antibacterianos
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
JP2004525108A (ja) * 2000-12-18 2004-08-19 キュービスト ファーマスーティカルズ インコーポレイテッド 精製リポペプチドの調製方法
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
WO2004017925A2 (en) * 2002-08-23 2004-03-04 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US20050277581A1 (en) * 2002-11-18 2005-12-15 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
EP2018864A1 (en) * 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
CA2713989A1 (en) * 2008-03-04 2009-09-11 Elan Pharma International Limited Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens
EP3338791B1 (en) 2008-07-17 2019-09-18 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin in the treatment or prophylaxis of heart failure
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
AU2009302478B2 (en) 2008-10-07 2015-09-03 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
CN102325532B (zh) 2008-10-07 2015-06-17 Mpex医药有限公司 用于减轻肺部炎症的左氧氟沙星吸入剂
WO2010048630A1 (en) 2008-10-24 2010-04-29 Los Angeles Biomedical Reserch Institute At Harbor-Ucla Medical Center Anti-infective hydroxy-phenyl-benzoates and methods of use
NZ594019A (en) * 2008-12-22 2013-08-30 Cubist Pharm Inc Novel antibacterial agents for the treatment of gram positive infections
WO2010075416A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CA2767614C (en) * 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
US8450300B2 (en) * 2009-07-13 2013-05-28 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
LT2473170T (lt) 2009-09-04 2019-10-10 Horizon Orphan Llc Aerozolizuoto levofloksacino panaudojimas cistinės fibrozės gydymui
CA2781666C (en) 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2013059610A1 (en) * 2011-10-20 2013-04-25 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
PL4066849T3 (pl) * 2012-09-11 2025-06-16 Hospira Australia Pty Ltd Preparaty daptomycyny i ich zastosowania
CN103006562B (zh) * 2013-01-21 2014-09-17 西南大学 达托霉素醇质体制剂
WO2014152332A1 (en) 2013-03-15 2014-09-25 Melinta Therapeutics, Inc. Methods of treating infections in overweight and obese patients using antibiotics
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
JP2019515007A (ja) * 2016-05-13 2019-06-06 スペロ ポテンシエーター インコーポレイテッドＳｐｅｒｏ Ｐｏｔｅｎｔｉａｔｏｒ， Ｉｎｃ． 新規カチオン性ペプチドｓｐｒ７４１による、抗生物質活性の増強
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
US4800157A (en) 1985-09-09 1989-01-24 Eli Lilly And Company Process for producing the A-21978C antibiotics
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
CA2011365A1 (en) * 1989-03-06 1990-09-06 Eugene L. Inman Diluent formulation for daptomycin
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
FR2772272B1 (fr) * 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
HU230656B1 (hu) 1998-09-25 2017-06-28 Cubist Pharmaceuticals Llc Daptomicin alkalmazása
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device

Also Published As

Publication number Publication date
JP2006335773A (ja) 2006-12-14
RU2004106569A (ru) 2005-08-10
EP1115417B1 (en) 2006-04-05
PL203689B1 (pl) 2009-11-30
NL300232I1 (nl) 2006-09-01
CN1348382A (zh) 2002-05-08
ATE322280T1 (de) 2006-04-15
AU6268799A (en) 2000-04-17
ES2259845T3 (es) 2006-10-16
PT1674107T (pt) 2016-12-07
RU2363489C9 (ru) 2010-03-20
NO20011454L (no) 2001-05-25
NL300232I2 (nl) 2007-01-02
CN1530136A (zh) 2004-09-22
CA2344318C (en) 2006-07-04
HK1040363B (en) 2007-01-26
IS8807A (is) 2009-03-10
JP4184607B2 (ja) 2008-11-19
WO2000018419A3 (en) 2000-07-06
HK1040363A1 (en) 2002-06-07
KR20100051735A (ko) 2010-05-17
DE122006000049I2 (de) 2007-11-08
CA2344318A1 (en) 2000-04-06
DE122006000049I1 (de) 2007-01-04
RU2363489C2 (ru) 2009-08-10
HUP0103874A2 (hu) 2002-02-28
CY2006003I1 (el) 2009-11-04
AU764348B2 (en) 2003-08-14
DK1115417T3 (da) 2006-07-31
CN1150029C (zh) 2004-05-19
CY2006003I2 (el) 2009-11-04
JP2002525335A (ja) 2002-08-13
SI1674107T1 (sl) 2017-01-31
EP1674107A2 (en) 2006-06-28
JP2004339238A (ja) 2004-12-02
NZ510690A (en) 2002-10-25
PT1115417E (pt) 2006-07-31
DK1674107T3 (en) 2016-12-19
LU91254I2 (fr) 2006-08-28
DE69930758T2 (de) 2007-04-26
CY1105556T1 (el) 2010-07-28
PL206091B1 (pl) 2010-06-30
NO20011454D0 (no) 2001-03-22
US6468967B1 (en) 2002-10-22
SI1115417T1 (sl) 2006-08-31
DE69930758D1 (de) 2006-05-18
KR20010075327A (ko) 2001-08-09
IS5890A (is) 2001-03-14
JP2003321389A (ja) 2003-11-11
US6852689B2 (en) 2005-02-08
HUP0103874A3 (en) 2002-09-30
BR9914051A (pt) 2001-06-19
EP1674107A8 (en) 2006-10-04
WO2000018419A2 (en) 2000-04-06
US20020142948A1 (en) 2002-10-03
EP1674107A3 (en) 2012-06-20
ES2603086T3 (es) 2017-02-23
EP1674107B1 (en) 2016-08-24
EP1674107B8 (en) 2017-01-25
PL348328A1 (en) 2002-05-20
CY1118334T1 (el) 2017-06-28
EP1115417A2 (en) 2001-07-18
HU230656B1 (hu) 2017-06-28

Similar Documents

Publication Publication Date Title
PT1115417E (pt) Utilizacao da daptomicina
PT101289A (pt) Utilizacao de taxol para a preparacao de composicoes farmaceuticas de eficacia melhorada
EA200300045A1 (ru) Композиция и лекарственная форма для задерживаемого желудочного выделения алендроната и/или других бис-фосфонатов
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
TR199903257T2 (tr) Ensülin direncinin büyüme hormonu sekretagoglari ile tedavisi.
PE20040555A1 (es) Profarmacos de aminoacidos excitadores
TR200002969T2 (tr) Farmasötik bileşim.
EP1118336A3 (en) Somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
TR200200913T2 (tr) Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları.
WO2002064214A8 (en) Anti cancer combination of substituted pyrroles and paclitaxel
HUP0000110A2 (hu) Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények
PT1003554E (pt) Inibidor da bomba de protoes em combinacao terapeutica com substancias antibacterianas
RU2015152175A (ru) Комбинация ro5503781, капецитабина и оксалиплатина для терапии рака
TR199801024T2 (tr) Mide-bagirsak düzensizliklerinin engellenmesi ve iyilestirilmesi için, bizmut ve bir ya da daha çok antimikrobik madde ihitva eden bilesimler.
RO122835B9 (ro) Utilizarea dietilaminei ca analgezic în preparate farmaceutice
RU2015152577A (ru) Комбинация ro5503781 и капецитабина для лечения рака
CY1113562T1 (el) Σκευασματα τομπραμυκινης για τη θεραπεια ενδοβρογχικων λοιμωξεων
UA10769C2 (uk) Лікарський засіб для профілактики передчасhого старіhhя та лікуваhhя вікових патологій